Marksans Pharma Ltd
NSE:MARKSANS

Watchlist Manager
Marksans Pharma Ltd Logo
Marksans Pharma Ltd
NSE:MARKSANS
Watchlist
Price: 220.8 INR -2.3%
Market Cap: 100.1B INR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

MARKSANS Price Targets Summary
Marksans Pharma Ltd

Wall Street analysts forecast MARKSANS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MARKSANS is 299.88 INR with a low forecast of 267.65 INR and a high forecast of 339.15 INR.

MARKSANS Lowest Forecast
Wall Street Target
267.65 INR
21% Upside
MARKSANS Average Forecast
Wall Street Target
299.88 INR
36% Upside
MARKSANS Highest Forecast
Wall Street Target
339.15 INR
54% Upside
Lowest
Price Target
267.65 INR
21% Upside
Average
Price Target
299.88 INR
36% Upside
Highest
Price Target
339.15 INR
54% Upside
Marksans Pharma Ltd Competitors:
Price Targets
IPN
Ipsen SA
17% Upside
AGY
Allergy Therapeutics PLC
104% Upside
IPCALAB
IPCA Laboratories Ltd
20% Upside
300401
Zhejiang Garden Bio-chemical High-tech Co Ltd
26% Upside
IPN
Ipsen SA
17% Upside
AGY
Allergy Therapeutics PLC
104% Upside
IPCALAB
IPCA Laboratories Ltd
20% Upside
300401
Zhejiang Garden Bio-chemical High-tech Co Ltd
26% Upside
NEU
Neuren Pharmaceuticals Ltd
119% Upside
ROG
Roche Holding AG
6% Upside
000538
Yunnan Baiyao Group Co Ltd
23% Upside
CLSD
Clearside Biomedical Inc
503% Upside

Revenue
Forecast

Revenue Estimate
Marksans Pharma Ltd

For the last 8 years the compound annual growth rate for Marksans Pharma Ltd's revenue is 12%. The projected CAGR for the next 3 years is 19%.

12%
Past Growth
19%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Marksans Pharma Ltd

For the last 8 years the compound annual growth rate for Marksans Pharma Ltd's operating income is 18%. The projected CAGR for the next 3 years is 26%.

18%
Past Growth
26%
Estimated Growth
Estimates Accuracy
-38%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Marksans Pharma Ltd

For the last 8 years the compound annual growth rate for Marksans Pharma Ltd's net income is 19%. The projected CAGR for the next 3 years is 26%.

19%
Past Growth
26%
Estimated Growth
Estimates Accuracy
-32%
Average Miss
What are analyst estimates?

See Also

Summary
MARKSANS intrinsic value, competitors valuation, and company profile.
DCF Valuation
MARKSANS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MARKSANS stock valuation using valuation multiples.
Wall Street Estimates
MARKSANS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MARKSANS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MARKSANS's stock price target?
Price Target
299.88 INR

According to Wall Street analysts, the average 1-year price target for MARKSANS is 299.88 INR with a low forecast of 267.65 INR and a high forecast of 339.15 INR.

What is Marksans Pharma Ltd's Revenue forecast?
Projected CAGR
19%

For the last 8 years the compound annual growth rate for Marksans Pharma Ltd's revenue is 12%. The projected CAGR for the next 3 years is 19%.

What is Marksans Pharma Ltd's Operating Income forecast?
Projected CAGR
26%

For the last 8 years the compound annual growth rate for Marksans Pharma Ltd's operating income is 18%. The projected CAGR for the next 3 years is 26%.

What is Marksans Pharma Ltd's Net Income forecast?
Projected CAGR
26%

For the last 8 years the compound annual growth rate for Marksans Pharma Ltd's net income is 19%. The projected CAGR for the next 3 years is 26%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 241,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.